Oxford BioMedica (LON:OXB) Stock Passes Below Two Hundred Day Moving Average of $639.37

Oxford BioMedica plc (LON:OXB) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $639.37 and traded as low as $553.00. Oxford BioMedica shares last traded at $567.00, with a volume of 37,899 shares.

A number of research analysts have weighed in on OXB shares. Peel Hunt reaffirmed a “buy” rating on shares of Oxford BioMedica in a research report on Monday, November 4th. Liberum Capital reaffirmed a “buy” rating on shares of Oxford BioMedica in a research report on Friday, November 15th.

The stock has a market capitalization of $427.47 million and a price-to-earnings ratio of -48.88. The company has a debt-to-equity ratio of 10.55, a current ratio of 2.21 and a quick ratio of 1.80. The business’s 50-day simple moving average is GBX 547.02 and its two-hundred day simple moving average is GBX 638.82.

In other Oxford BioMedica news, insider Martin Diggle purchased 17,953 shares of Oxford BioMedica stock in a transaction on Thursday, September 12th. The shares were purchased at an average cost of GBX 577 ($7.54) per share, with a total value of £103,588.81 ($135,357.13). Also, insider Lorenzo Tallarigo purchased 482 shares of Oxford BioMedica stock in a transaction on Wednesday, September 25th. The shares were acquired at an average cost of GBX 554 ($7.24) per share, for a total transaction of £2,670.28 ($3,489.19).

About Oxford BioMedica (LON:OXB)

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Recommended Story: Why Dividend Stocks May Be Right for You

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.